-

Labcorp Opens New Los Angeles Based Laboratory

New Space Will Be Three Times Larger and Increase Testing Capabilities

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities.

Labcorp is investing in its APH services as a key component of its global growth and expansion strategy. The new laboratory is a dedicated Center of Excellence focused on APH laboratory testing solutions. The larger laboratory will expand capabilities, such as digital pathology with the use of artificial intelligence (AI), multiplex immunohistochemistry (IHC) and other innovative technologies supporting clinical trials and precision medicine development.

“Our larger, state-of-the-art laboratory allows us to further advance clinical trials across numerous therapeutic areas like oncology, hemato-oncology and liver disease,” said Vincent Drouillon, senior vice president of global testing services and scientific and medical affairs for Labcorp Drug Development’s Clinical Trial Testing Solutions business. “Additionally, it will enable us to increase capacity and to enhance capabilities of our APH services offering, including exploratory biomarkers, fully validated tests, international quality standards and companion diagnostics.”

Most of the new laboratory space can be reconfigured without construction, enabling fast adjustment for new technologies, spikes in demand and changes in workflow. In addition to the flexibility of design, the new laboratory can also be expanded for future growth.

The Los Angeles facility complements the broader global central laboratory and specialty testing capabilities of Labcorp. Additional global growth includes recent expansions to Labcorp’s APH laboratories in Singapore and Switzerland, as well as the opening of an APH lab section in Japan.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Media: Rachael Valdez – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

Labcorp

NYSE:LH
Details
Headquarters: Burlington, NC
CEO: Adam Schechter
Employees: 75,000
Organization: PUB
Revenues: $16.1 billion (2021)
Net Income: $2.37 billion (2021)

Release Versions

Contacts

Media: Rachael Valdez – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

More News From Labcorp

Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

BOSTON--(BUSINESS WIRE)--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans. According to the National Institute on Aging (NIA), more than 1 million women trans...

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In 2022, we also advanced our strategy with the announcement of the spin of our Clinical...

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial ma...
Back to Newsroom